Nordic Nanovector GmbH

Swiss Biotech Association

Not a member

A biopharmaceutical company developing antibody radionuclide conjugates for haematological cancers with their lead molecule Betalutin in Phase I and IIb studies.

http://www.nordicnanovector.com

Location

Dammstrasse 19, 6300 Zug, Switzerland

Get Directions

Facts & figures

Type of organization

Public company
Year of foundation

2009
Number of employees in Switzerland

1-9

Key business

Core competencies

Therapeutics/vaccines (human)

You may also be interested in

CELLnTEC Advanced Cell Systems

CELLnTEC technologies enable science and industry to develop innovations in stem cell research, regenerative medicine, cell-based therapies, and beyond. The company is a pioneering developer of chemically defined, animal and human components-free precision media.
3014 Bern

Member

Caland SA

Caland SA provides a professional, confidential, competitive and impeccable service of pharma-grade CO2 extraction, distillation and cannabis formulation based on GMP requirements.
A modern production line, coupled to a qualified ERP, ensures uncompromising quality of all products and services.
2800 Delémont

Member

Curare Swiss AG

Curare provides strategic advice to assist in the successful design of R&D programs. From the non-clinical to clinical Proof-of-Concept. The right decisions at the right time. Curare's experts put their years of experience and knowledge relating to translational and clinical drug development to use.
4056 Basel

Member